Regulatory Roundup: FDA Provides Information on Advisory Committees, Announces Public Meetings, And More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Provides Information on Advisory Committees, Announces Public Meetings, And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The FDA Transparency Blog now hosts a section about the agency’s advisory committees. The blog is part of the US Food and Drug Administration’s efforts to provide information about how the agency works to industry and the general public. The new section appears on the blog and on the FDA Basics web page and offers a Q&A about what advisory committees are, how members are selected, and how the committees contribute to larger FDA's decisions about drugs.

FDA will hold two public meetings taking place this September. The first meeting, taking place Sept. 17, in Rockville, Maryland, is meant to solicit stakeholder input on the development of a generic-drug user-fee program. According to the FDA announcement, “a user fee program could provide necessary supplemental funding, in addition to current Congressional appropriations, to allow for the timely review of such applications. Although the President’s Fiscal Year (FY) 2011 budget includes generic drug user fees, new legislation would be required for FDA to establish and collect user fees under such a program.”

The second hearing, taking place Sept. 27 and 28, in Silver Spring, Maryland, will address a new framework for the development and distribution of patient medication information for prescription products. The agency says that the current system of providing information to patients, which may include duplicates or be difficult to understand, needs to be revised. The agency is seeking input about the use of a single standardized document to include drug-product information.

Per its June 2010 guidance for industry on bioequivalence recommendations, FDA has updated its listing of individual product bioequivalence recommendations regarding active pharmaceutical ingredients. The updates include 26 new recommendations and 10 revised recommendations.

The agency also updated its adverse-event reporting system (AERS) database to include information from the second quarter of 2010 (i.e., from April to June). The database lists the names of products, potential signals of serious risks, and new safety information that was identified for the products during the review period. FDA posted the information as part of the 2007 Food and Drug Administration Amendments Act of 2007.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here